slides · global inventory
Expose Contradiction
Slide function collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 14,162
Current window 9,361-9,390
Pages 473
Rows per page 30
Slide function
9,361-9,390 of 14,162
151
Uses anecdotal evidence from Facebook patient support groups to highlight a safety gap.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
152
The slide uses red underlining to highlight specific dangerous medical advice given to patients.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
154
The slide uses a 'villain critique' style to frame the FDA's approval as flawed and the drug's safety as compromised.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
155
The slide uses a narrative summary followed by a supporting table (Table 4) to challenge the safety reporting of the drug.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
156
The slide uses a combination of narrative analysis and a specific case study excerpt to challenge the safety profile of pitolisant.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
157
The slide presents clinical case summaries to address potential safety concerns regarding cardiac events.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
158
The slide uses direct quotes from FDA clinical reviews to highlight the discrepancy between pre-approval assumptions and post-approval safety signals.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
161
The slide uses a 'fraud-exposure' or 'investigative' tone to question the lack of public data on a specific study.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
163
The slide uses a 'villain' narrative to frame the company's non-disclosure as intentional concealment.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
164
The slide uses a combination of original analysis and cited medical literature to challenge the transparency of clinical trial reporting.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
167
The slide uses a medical reference to re-frame clinical trial data that was previously dismissed as unrelated.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
169
The slide uses a direct quote from an FDA clinical review to demonstrate a lack of oversight regarding a specific medical signal.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
170
The slide uses a combination of narrative argument and a cited abstract to highlight a potential safety oversight.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
174
The slide argues that reporting lags or manipulation by Harmony Biosciences obscures the true number of adverse events.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
175
The slide uses a list of adverse events to build a case for cardiotoxicity, highlighting specific fatal and serious outcomes.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
178
The slide highlights a potential discrepancy between official FDA reporting and actual event timing, suggesting either database lag or manufacturer reporting delays.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
184
The slide highlights a potential cover-up or reporting discrepancy regarding a patient seizure.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
185
The slide presents a narrative summary of a medical case report, pointing out suspicious physician/company behavior regarding the reporting of heart palpitations.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
192
The slide highlights a specific safety concern regarding pitolisant (Wakix) and its interaction with CYP2D6 inhibitors.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
193
The slide uses a narrative structure to expose a potential cover-up or reporting failure regarding a serious adverse event.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
201
The slide presents a patient-reported adverse event (FAERS) to challenge the safety profile of a pharmaceutical product.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
202
The slide explicitly frames the narrative as a potential cover-up, contrasting patient statements with official physician office clarifications.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
204
The slide highlights a discrepancy between the drug's safety profile as presented and the real-world experience of a physician.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
207
The slide uses a Q&A format to document a specific interaction between a doctor and a pharmaceutical sales representative.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
209
The slide uses a table to contrast the clinical trial design with the author's thesis that the evidence standard is too low.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
210
The slide uses a table of clinical trials alongside red-text annotations to highlight the geographic and temporal distance of the studies.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
211
The slide uses a table from a Lancet paper to argue that pitolisant's performance was inferior to modafinil, contradicting the company's narrative.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
212
The slide uses a pie chart to highlight that 38% of study participants were in Russia, suggesting a lack of geographic diversity and potential data manipulation.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
213
The slide uses a combination of narrative text and specific evidence (EMA table and ClinicalTrials.gov record) to prove the existence of a suppressed trial.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
214
The slide uses excerpts from French regulatory documents to prove the existence and negative results of the unpublished HARMONY 4 trial.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit